Respiratory

• Market Access

GSK’s Nucala secures NICE COPD endorsement

pharminent May 29, 2026

• Clinical Data

ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD

pharminent May 21, 2026

• Clinical Data

ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis

pharminent May 21, 2026

• Regulatory

Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

pharminent May 18, 2026

• Regulatory

Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

pharminent May 18, 2026

• Clinical Data

Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis

pharminent May 12, 2026

• M&A / Deals

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

pharminent April 30, 2026

• M&A / Deals

Avalyn seeks public debut to support new lung drug formulations

pharminent April 24, 2026

• Clinical Data

AZ is three for three with COPD hope tozorakimab

pharminent April 20, 2026

• Other

Pulmonary fibrosis drug developer Avalyn files IPO

pharminent April 9, 2026

• Other

Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic

pharminent April 9, 2026

• Pipeline

Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway

pharminent April 8, 2026

• Clinical Data

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

pharminent March 27, 2026